News & Updates

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

01/24/2023

Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / January 19, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically,…

Read More

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

01/23/2023

Compass to Host Investor Event on Monday, January 23rd at 8:30am ET Excerpt from the Press Release: BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the presentation of data from a Phase 2 study of…

Read More

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

01/23/2023

IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential…

Read More

Vial Announces Enrollment of First Patient in Phase II Clinical Trial TLL018-205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical

01/23/2023

Excerpt from the Press Release: SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ — Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial TLL018-205, a Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of TLL-018 in human subjects with moderate…

Read More

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

01/20/2023

Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., Jan. 12, 2023…

Read More

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

01/20/2023

Excerpt from the Press Release: CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a…

Read More

Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs

01/20/2023

Company will launch the eXpDNA Platform at Phacilitate Advanced Therapies Week Excerpt from the Press Release: WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience. The platform significantly reduces plasmid development and production…

Read More

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

01/19/2023

-StealthX™Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- Excerpt from the Press Release: SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today…

Read More

Thermo Fisher Scientific Joins Momentum Labs as Founding Sponsor of New Biotech Hub in Alachua, Florida

01/19/2023

Collaborative lab space enables development and growth of the next generation of life science companies in the greater Gainesville region Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–As part of its efforts to support emerging biotechnology companies with addressing key challenges of bringing new therapies to market, Thermo Fisher Scientific today announced it has become…

Read More

Meet with Christopher Kata and the TrialStat team (booth # 906), during the SCOPE Summit, February 6th – 9th, in Orlando!

01/19/2023

Meet with Christopher Kata, Director of Sales & Marketing February 6th – 9th, 2023 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 906. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 6th…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives